HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Xtreme Tylenol: Wakeboarding, Olympics And Indie Film Festivals

This article was originally published in The Tan Sheet

Executive Summary

Recent edgy Tylenol promotions, which contrast sharply with previous traditional ads, reflect a dramatic change in marketing that coincides with McNeil Consumer & Specialty Pharmaceuticals' decision to switch ad agencies last year

You may also be interested in...



U.S. Olympic Teams Hoist P&G Brand In Vancouver, London Games

Procter & Gamble will sponsor "the most positively viewed sports property in the United States" under an alliance with the U.S. Olympic Committee

FDA’s Rosebraugh Commends Ads Addressing Conscientious OTC Use

Drug marketers who communicate that their OTC products should be taken with the same care as prescription drugs are sending the right message, according to Curtis Rosebraugh, MD, deputy director of FDA's Office of Nonprescription Products

McNeil advertising

Tylenol advertising account, reportedly valued at $100 mil., has been awarded to Deutsch (New York), McNeil Consumer & Specialty Pharmaceuticals announces Nov. 26. Deutsch also received St. Joseph's aspirin account, valued at more than $20 mil. Accounts for heartburn OTCs Pepcid AC ($48 mil.) and Mylanta ($16 mil.) went to Alchemy, which, like Deutsch, is owned by Interpublic group. All accounts were previously handled by New York-based Saatchi & Saatchi, which developed new Maximum Strength Pepcid AC ads that broke Nov. 24...

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS127744

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel